CLuptake, hep | CLuptake, slicea | fub | RBb | fB | CLh, int, allb | CLsec, int, allb | Scaling Factorc | CLsecb | |
---|---|---|---|---|---|---|---|---|---|
ml · min−1 · kg−1 | ml · min−1 · kg−1 | ml · min−1 · kg−1 | |||||||
Rosuvastatin | 15.1 | 3.30 | 0.12 | 0.69 | 0.174 | 104 | 27.0 | 8.2 | 3.92 |
Pravastatin | 13.8d | 0.447 | 0.55 | 0.56 | 0.989 | 23.3 | 16.6 | 37 | 9.47 |
Pitavastatin | 446d | 0.957 | 0.0052 | 0.58 | 0.009 | 411 | 3.34 | 3.5 | 0.03 |
Valsartan | 18.9 | 2.38 | 0.04 | 0.55 | 0.073 | 8.95 | 1.80 | 0.7 | 0.129 |
Olmesartan | 12.1 | 3.13 | 0.01 | 0.55 | 0.018 | 18.6 | 11.1 | 3.5 | 0.204 |
Trichlormethiazide | 1.01 | 0.29 | 0.55 | 0.527 | 10.7 | 11 | 4.54 | ||
PAH | 0.482 | 0.83 | 0.70 | 1.19 | N.A. | N.A. | 13.6 | ||
Fexofenadine | 0.347e | 0.31 | 0.55 | 0.564 | 1.52 | 4.4 | 0.658 | ||
Methotrexate | 0.168f | 0.37 | 0.83 | 0.446 | 1.40 | 8.3 | 1.13 | ||
Benzylpenicillin | 0.508 | 0.56 | 0.66 | 0.843 | 5.71 | 11 | 5.26 | ||
Candesartan | 44.8 | 0.0027 | 0.55 | 0.005 | 67.2 | ||||
Atorvastatin | 169d | 0.0511 | 0.61 | 0.084 | 329 | ||||
Fluvastatin | 351d | 0.0037 | 0.52 | 0.007 | 3760 | ||||
Cerivastatin | 746g | 0.007 | 0.58 | 0.012 | 485 |
CLuptake, hep, uptake clearance by human hepatocytes; CLuptake, slice, corrected saturable uptake clearance by human kidney slices; CLh, int, all, observed hepatic overall intrinsic clearance; CLsec, int, all, observed renal secretion overall intrinsic clearance; CLsec, observed renal secretion clearance; N.A., not applicable.
↵a Saturable uptake clearance was corrected by uptake of benzylpenicillin. The details of this estimation are described in the text and Table 1.
↵b References cited are listed in Supplemental Table 1.
↵c Scaling factors were calculated by dividing CLsec, int, all by CLuptake, slice.
↵d Data from Watanabe et al. (2010a).
↵e Data from Matsushima et al. (2009).
↵f Data from Nozaki et al. (2007b).
↵g Data from Shitara et al. (2003).